Discover Sustainability, Journal Year: 2025, Volume and Issue: 6(1)
Published: Feb. 19, 2025
Language: Английский
ACS Materials Au, Journal Year: 2023, Volume and Issue: 3(6), P. 600 - 619
Published: Aug. 21, 2023
Over the past decade, therapeutic potential of nanomaterials as novel drug delivery systems complementing conventional pharmacology has been widely acknowledged. Among these nanomaterials, lipid-based nanoparticles (LNPs) have shown remarkable pharmacological performance and promising outcomes, thus gaining substantial interest in preclinical clinical research. In this review, we introduce main types LNPs used formulations such liposomes, nanoemulsions, solid lipid nanoparticles, nanostructured carriers, polymer hybrid focusing on their physicochemical properties potential. We discuss computational studies modeling techniques to enhance understanding how interact with cargo predict effectiveness interactions applications. also analyze benefits drawbacks various LNP production nanoprecipitation, emulsification, evaporation, thin film hydration, microfluidic-based methods, an impingement jet mixer. Additionally, major challenges associated industrial development, including stability sterilization, storage, regulatory compliance, reproducibility, quality control. Overcoming facilitating compliance represent key steps toward LNP's successful commercialization translation into settings.
Language: Английский
Citations
179
Pharmaceutical Development and Technology, Journal Year: 2022, Volume and Issue: 27(5), P. 525 - 544
Published: May 28, 2022
The bioavailability of drugs is dependent on several factors such as solubility and the administration route. A drug with poor aqueous solubility, therefore, poses challenges regards to its pharmaceutical advance ultimately biological usage. Lipid nanoparticles have been used in science due their importance green chemistry. Their biochemical properties ‘green’ materials processes mean they can be environmentally sustainable. Generally, lipid employed carriers for both lipophilic hydrophilic drugs. proposed route present advantages disadvantages which should considered by a formulator. Solid (SLNs) nanostructured (NLCs) are attractive delivery systems because ease manufacture, biocompatibility, biodegradability, scale-up capacity formulation constituents. easy simple scalability novel SLNs nano carriers, along various processing procedures, recent developments, limitation toxicity, optimization approaches manufacture nanoparticles, lyophilization release comprehensively discussed this review. This review also summarizes research data related preparation methods excipients NLCs years.
Language: Английский
Citations
87
Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(2), P. 656 - 656
Published: Feb. 15, 2023
Skin delivery is an exciting and challenging field. It a promising approach for effective drug due to its ease of administration, handling, high flexibility, controlled release, prolonged therapeutic effect, adaptability, many other advantages. The main associated challenge, however, low skin permeability. healthy barrier that serves as the body's primary defence mechanism against foreign particles. New advances in (both topical transdermal) depend on overcoming challenges with molecule permeation irritation. These limitations can be overcome by employing new approaches such lipid nanosystems. Due their advantages (such easy scaling, cost, remarkable stability) these systems have attracted interest from scientific community. However, successful formulation, several factors including particle size, surface charge, components, etc. understood controlled. This review provided brief overview structure well different pathways nanoparticle penetration. In addition, influencing penetration nanoparticles been highlighted. Applications nanosystems dermal transdermal delivery, regulatory aspects, were critically discussed.
Language: Английский
Citations
78
Biomedicines, Journal Year: 2022, Volume and Issue: 10(9), P. 2179 - 2179
Published: Sept. 2, 2022
Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery. With the prevalence of respiratory diseases, particularly highlighted by current COVID-19 pandemic, investigations into applying LNPs to deliver inhaled therapeutics directly lungs are underway. The progress in LNP development well recent pre-clinical studies three main classes encapsulated drugs: small molecules, nucleic acids and proteins/peptides will be discussed. advantages pulmonary delivery system such reducing systemic toxicity enabling higher local concentration evaluated together with challenges design considerations improved formulations. This review provides perspective on future prospects LNP-mediated diseases.
Language: Английский
Citations
73
Advanced Drug Delivery Reviews, Journal Year: 2023, Volume and Issue: 197, P. 114826 - 114826
Published: April 23, 2023
Language: Английский
Citations
71
Small, Journal Year: 2023, Volume and Issue: 19(36)
Published: April 29, 2023
Abstract The protein corona forms spontaneously on nanoparticle surfaces when nanomaterials are introduced into any biological system/fluid. Reliable characterization of the is, therefore, a vital step in development safe and efficient diagnostic therapeutic nanomedicine products. 2134 published manuscripts reviewed down‐selection 470 papers spanning 2000–2021, comprising 1702 (NP) systems is analyzed. This analysis reveals: i) most studies have been conducted metal oxide nanoparticles; ii) despite their overwhelming presence clinical practice, lipid‐based NPs underrepresented research, iii) use new methods to improve reliability reproducibility research; iv) more specific sources toward personalized medicine; v) careful nanoparticles after formation imperative minimize role aggregation contamination outcomes. As used biomedicine become increasingly prevalent biochemically complex, field research will need focus developing analytical approaches techniques appropriate for each unique formulation. Achieving such nano‐bio interface nanobiotechnologies enable seamless implementation medicine.
Language: Английский
Citations
66
Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 361, P. 130 - 146
Published: Aug. 4, 2023
Language: Английский
Citations
66
Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 358, P. 398 - 419
Published: May 12, 2023
Language: Английский
Citations
57
Journal of Drug Delivery Science and Technology, Journal Year: 2023, Volume and Issue: 86, P. 104709 - 104709
Published: July 3, 2023
Solid lipid nanoparticles (SLN) are considered at the forefront of nanotechnology's rapidly developing field, with several potential applications in drug delivery and research. SLN possesses promising attributes for reaching goal controlled site-specific hence attracted researchers' wide attention. The present review briefly introduces discusses reasoning behind use over other colloidal carriers, such as emulsions liposomes. Techniques to produce SLN, incorporation, loading capacity, release mechanisms reviewed. Aspects SLNs route administration vivo fate carriers also discussed. incorporating different anti-cancer drugs their effectiveness various cancer therapies is highlighted. mechanism action some commonly used agents provided.
Language: Английский
Citations
53
Advanced Materials, Journal Year: 2023, Volume and Issue: unknown
Published: Oct. 4, 2023
Abstract Lipid‐based nanoparticles (LBNPs) are currently the most promising vehicles for nucleic acid drug (NAD) delivery. Although their clinical applications have achieved success, NAD delivery efficiency and safety still unsatisfactory, which are, to a large extent, due existence of multi‐level physiological barriers in vivo. It is important elucidate interactions between these LBNPs, will guide more rational design efficient with low adverse effects facilitate broader therapeutics. This review describes obstacles challenges biological at systemic, organ, sub‐organ, cellular, subcellular levels. The strategies overcome comprehensively reviewed, mainly including physically/chemically engineering LBNPs directly modifying by auxiliary treatments. Then potentials successful translation preclinical studies into clinic discussed. In end, forward look on manipulating protein corona (PC) addressed, may pull off trick overcoming those significantly improve efficacy LBNP‐based NADs
Language: Английский
Citations
53